MACK - Merrimack Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
11.17
+0.05 (+0.45%)
At close: 4:00PM EST

11.17 0.00 (0.00%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close11.12
Open11.13
Bid10.27 x 500
Ask11.70 x 1000
Day's Range10.91 - 11.32
52 Week Range10.04 - 39.90
Volume116,333
Avg. Volume169,827
Market Cap148.996M
Beta2.20
PE Ratio (TTM)0.32
EPS (TTM)34.43
Earnings DateFeb 27, 2018 - Mar 5, 2018
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2017-05-30
1y Target Est14.50
Trade prices are not sourced from all markets
  • Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference
    PR Newswire19 days ago

    Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 4, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 9:00 a.m. PT in San Francisco. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers.

  • Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound?
    Zackslast month

    Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound?

    Merrimack (MACK) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
    PR Newswire2 months ago

    Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors

    CAMBRIDGE, Mass., Nov. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced the addition of George Demetri, M.D., a professor of medicine at Harvard Medical School and physician-scientist faculty member at the Dana-Farber Cancer Institute (DFCI), to its Board of Directors. Dr. Demetri, a world-renowned expert in the clinical translation of innovative treatment strategies for cancer, replaces John Mendelsohn, M.D., who is retiring from the Board.

  • With An ROE Of 175.74%, Has Merrimack Pharmaceuticals Inc’s (MACK) Management Done A Good Job?
    Simply Wall St.2 months ago

    With An ROE Of 175.74%, Has Merrimack Pharmaceuticals Inc’s (MACK) Management Done A Good Job?

    Merrimack Pharmaceuticals Inc (NASDAQ:MACK) outperformed the Biotechnology industry on the basis of its ROE – producing a higher 175.74% relative to the peer average of 16.08% over the past 12Read More...

  • Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team
    PR Newswire2 months ago

    Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team

    CAMBRIDGE, Mass., Nov. 14, 2017 /PRNewswire/ -- Torque, an immuno-oncology company developing Deep Primed™ cell therapies that direct and evoke immune responses in the tumor microenvironment, today announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed with $25 million in Series A capital by Flagship Pioneering. The Torque platform makes it possible to anchor powerful stimulatory cytokines, antibodies, and small molecules directly to immune cells to direct their activity and increase their efficacy and durability in the "hostile" tumor microenvironment, without systemic exposure.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MACK earnings conference call or presentation 8-Nov-17 1:30pm GMT

    Q3 2017 Merrimack Pharmaceuticals Inc Earnings Call

  • Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
    Zacks2 months ago

    Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up

    Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.

  • Associated Press2 months ago

    Merrimack beats 3Q profit forecasts

    The Cambridge, Massachusetts-based company said it had net income of 24 cents per share. Losses, adjusted to account for discontinued operations, were 40 cents per share. The results topped Wall Street ...

  • Merrimack's (MACK) Reports Narrower-than-Expected Q3 Loss
    Zacks2 months ago

    Merrimack's (MACK) Reports Narrower-than-Expected Q3 Loss

    Merrimack Pharmaceuticals (MACK) announced third quarter results with loss narrower than expected, however, revenues misses the same.

  • Merrimack Reports Third Quarter 2017 Financial Results
    PR Newswire3 months ago

    Merrimack Reports Third Quarter 2017 Financial Results

    - Received orphan drug designation for MM-121 in heregulin positive non-small cell lung cancer - - Resolved convertible note litigation associated with asset sale to Ipsen S.A. and commenced tender offer ...

  • ACCESSWIRE3 months ago

    Merrimack Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 8:30 ...

  • What's in the Cards for Merrimack (MACK) in Q3 Earnings?
    Zacks3 months ago

    What's in the Cards for Merrimack (MACK) in Q3 Earnings?

    Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

  • ACCESSWIRE3 months ago

    Featured Company News - FDA Granted Orphan Drug Designation to Merrimack's MM-121 for Treatment of Heregulin Positive Non-Small Cell Lung Cancer

    Research Desk Line-up: Seattle Genetics Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 1, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...

  • Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121
    SmarterAnalyst3 months ago

    Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121

    Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that indoximod, its investigational drug candidate, was granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of heregulin positive non-small cell lung cancer. "This is an important regulatory step forward for the clinical development of MM-121 in non-small cell lung cancer and we are pleased to have access to additional support from the FDA in this indication," said Sergio Santillana, M.D., MSc, Chief Medical Officer.

  • TheStreet.com3 months ago

    NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

    The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.

  • PR Newswire3 months ago

    Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer

    CAMBRIDGE, Mass. , Oct. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MM-121, ...

  • Have Investors Already Priced In Merrimack Pharmaceuticals Inc’s (MACK) Growth?
    Simply Wall St.3 months ago

    Have Investors Already Priced In Merrimack Pharmaceuticals Inc’s (MACK) Growth?

    Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a biotechnology company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...

  • PR Newswire3 months ago

    Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020

    ISIN No. US590328AA86) (the "Notes"), which amount reflects the consummation of the purchase of the Notes from the Settlement Noteholders (as defined herein) pursuant to the Settlement Agreement (as defined herein). The Company agreed to conduct the Tender Offer in connection with the settlement agreement (the "Settlement Agreement") that it entered into on October 6, 2017 with Wolverine Flagship Fund Trading Limited, 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P. (collectively, the "Settlement Noteholders") and Wells Fargo Bank, National Association (the "Trustee") to resolve the lawsuit pending in the Court of Chancery in the State of Delaware captioned Wells Fargo Bank, N.A., et al. v. Merrimack Pharmaceuticals, Inc., C.A. No. 2017-0199-JTL filed by the Settlement Noteholders and the Trustee.

  • Merrimack Pharmaceuticals Inc (MACK): How Does It Impact Your Portfolio?
    Simply Wall St.3 months ago

    Merrimack Pharmaceuticals Inc (MACK): How Does It Impact Your Portfolio?

    If you are a shareholder in Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • PR Newswire3 months ago

    Merrimack Announces Settlement of Convertible Note Litigation

    CAMBRIDGE, Mass., Oct. 10, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that it has reached a settlement agreement with Wolverine Flagship Fund Trading Limited, 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P. (collectively, "Noteholder Plaintiffs") and Wells Fargo Bank, National Association, to resolve the previously disclosed lawsuit captioned Wells Fargo Bank, N.A., et. al. v. Merrimack Pharmaceuticals, Inc. pending in the Court of Chancery in the State of Delaware (the "Delaware Action").

  • Is It Time To Buy Merrimack Pharmaceuticals Inc (MACK)?
    Simply Wall St.4 months ago

    Is It Time To Buy Merrimack Pharmaceuticals Inc (MACK)?

    Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a pharmaceuticals, biotechnology and life sciences company based in United States, saw a significant share price rise of over 20% in the past couple of monthsRead More...

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: American Superconductor and Merrimack Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 7, 2017 / After posting the worst daily drop in weeks on rising geopolitical tensions between North Korea and the from their worst daily drop in weeks, U.S. markets ...

  • TheStreet.com5 months ago

    Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

    Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.

  • Merrimack Announces Date of One-for-Ten Reverse Stock Split
    PR Newswire5 months ago

    Merrimack Announces Date of One-for-Ten Reverse Stock Split

    CAMBRIDGE, Mass., Aug. 31, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that the previously disclosed one-for-ten reverse stock split of its issued and outstanding common stock will be effective for trading purposes as of the commencement of trading on September 6, 2017. Merrimack's stockholders approved an amendment to the Company's certificate of incorporation to effect the reverse stock split at the Annual Meeting of Stockholders on August 11, 2017.

  • PR Newswire5 months ago

    Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer

    CAMBRIDGE, Mass., Aug. 14, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that it has strengthened its executive management team with the appointment of Jean M. Franchi as Chief Financial Officer, effective August 21, 2017. In this role, Ms. Franchi will plan and oversee Merrimack's financial strategy to support the ongoing development of multiple clinical- and preclinical-stage product candidates for cancer. Over the course of a 30-year career in the biotechnology and life sciences sectors, Ms. Franchi has held senior financial management roles at several leading companies spanning all stages of development, from research to commercial.